Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

43

Revenue 2017

Perjeta

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Perjeta was produced by Roche.

Roche submits Kadcyla for FDA Real-Time review

Roche submits Kadcyla for FDA Real-Time review Herceptin and follow-up Perjeta are already approved for neoadjuvant use in this indication, but it doesn’t always clear away all tumour tissue, which could dramatically increase the risk of

Ocrevus helps Roche shrug off biosimilars in 2018

Ocrevus helps Roche shrug off biosimilars in 2018 All told, new products accounted for 90% of Roche’s sales growth in 2018, with another big boost provided by the company’s breast cancer drug Perjeta (pertuzumab), up 27% to

Roche preps new Kadcyla filings after phase 3 trial win

Roche preps new Kadcyla filings after phase 3 trial win Neoadjuvant therapy is given with the intention of achieving a cure for patients with early-stage cancer, and Herceptin and follow-up HER2 drug Perjeta (pertuzumab) have been approved for this ... With Herceptin and follow-up Perjeta (pertuzumab) already

Ocrevus surge keeps Roche smiling in Q3

Ocrevus surge keeps Roche smiling in Q3 However, the performance of Ocrevus and other drugs such as HER2 breast cancer therapy Perjeta (pertuzumab) and lung cancer therapy Alecensa (alectinib) – plus a strong showing in Asia-Pacific markets led

Daiichi-Sankyo takes rival to Roche’s Kadcyla into phase 3

Daiichi-Sankyo takes rival to Roche’s Kadcyla into phase 3 mate Perjeta (pertuzumab).

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics